U.S. Markets open in 6 hrs 19 mins

If You Had Bought Genmab (CPH:GMAB) Stock Five Years Ago, You Could Pocket A 252% Gain Today

Simply Wall St

The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put in. But on the bright side, you can make far more than 100% on a really good stock. Long term Genmab A/S (CPH:GMAB) shareholders would be well aware of this, since the stock is up 252% in five years.

Check out our latest analysis for Genmab

While markets are a powerful pricing mechanism, share prices reflect investor sentiment, not just underlying business performance. One flawed but reasonable way to assess how sentiment around a company has changed is to compare the earnings per share (EPS) with the share price.

During five years of share price growth, Genmab achieved compound earnings per share (EPS) growth of 36% per year. The EPS growth is more impressive than the yearly share price gain of 29% over the same period. Therefore, it seems the market has become relatively pessimistic about the company. Having said that, the market is still optimistic, given the P/E ratio of 61.72.

You can see below how EPS has changed over time (discover the exact values by clicking on the image).

CPSE:GMAB Past and Future Earnings, January 21st 2020

Dive deeper into Genmab's key metrics by checking this interactive graph of Genmab's earnings, revenue and cash flow.

A Different Perspective

We're pleased to report that Genmab shareholders have received a total shareholder return of 47% over one year. That's better than the annualised return of 29% over half a decade, implying that the company is doing better recently. Given the share price momentum remains strong, it might be worth taking a closer look at the stock, lest you miss an opportunity. It's always interesting to track share price performance over the longer term. But to understand Genmab better, we need to consider many other factors. Take risks, for example - Genmab has 1 warning sign we think you should be aware of.

Of course Genmab may not be the best stock to buy. So you may wish to see this free collection of growth stocks.

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on DK exchanges.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Thank you for reading.